Health Canada grants two DIN to new Tetra Bio-pharma OTC products
Category: #health  By Saipriya Iyer  Date: 2020-01-21
  • share
  • Twitter
  • Facebook
  • LinkedIn

Health Canada grants two DIN to new Tetra Bio-pharma OTC products

Tetra Bio-pharma, a renowned Canadian biopharmaceutical company, reportedly announced that Health Canada, the regulatory health authority of Canada, has granted two new DIN (Drug Identification Numbers) for the first OTC (over-the-counter) products to be sold under the banner of TERPACAN™.

TERPACAN (hemorrhoids) is an innovative topical formulation that would be used to treat hemorrhoids, a painful, itchy and common condition that affects thousands of Canadians. Meanwhile, TERPACAN™ (muscle and back pain) is indicated for temporary relief of pains and aches of joints and muscles associated with lumbago, backache, strains, sprains, bruises, rheumatic or arthritic pain and pain of ligaments and tendons.

The country’s hemorrhoid therapy market has reached up to $22 million, showing a steady 3% CAGR in 2019. Moreover, the heavily competitive self-care pain therapy industry has reached $432 million, recording a CAGR of 1%.

The company is currently in the process of finalizing sales, supply, and distribution contracts with several organizations, and estimates the launching of TERPACAN™ products in pharmacy retail stores of Canada by mid-2020. Furthermore, Tetra would also launch these products into the European and American markets in 2020, once the company gains final marketing approval in those regions.

CEO and Chief Regulatory Officer at Tetra Bio-Pharma, Dr. Guy Chamberland stated that the company is focusing on bringing well-differentiated treatments for patients that are looking at novel options to help relieve the discomfort and pain associated with daily living activities.

Chamberland further added that Terpacan for muscle and back pain, and Terpacan to treat hemorrhoids, are the products that fall in line with the company’s vision. Additionally, as consumers would be able to get these medicines at their corner drugstores, it means easy access for caregivers and patients.

As per the Canadian Digestive Health Foundation, about 20 million Canadians go through a digestive problem each year, and hemorrhoids are one of the associated conditions that create an opportunity for the awareness of self-help cures. Meanwhile, U.S. estimates suggest that this problem affects about 4.5% of the total U.S. population.

The company had submitted these two applications for DIN of these OTC products back in November 2019.

 

Source credit: https://ir.tetrabiopharma.com/newsroom/press-releases/news-details/2020/Tetra-Bio-Pharma-Granted-Two-OTC-Drug-Identification-Numbers-DIN-by-Health-Canada/default.aspx



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Copper3D unveils antimicrobial device to curb HIV risk via breastmilk
Copper3D unveils antimicrobial device to curb HIV risk via breastmilk
By Saipriya Iyer

Copper3D, a Chile- and U.S.-based antibacterial solutions provider, has recently worked on a project to create an antibacterial 3D printed device to mitigate the risk of HIV transmission during breastfeeding. The compa...

Tetra commences PoC clinical trial of PPP003v for companion dogs
Tetra commences PoC clinical trial of PPP003v for companion dogs
By Saipriya Iyer

Tetra Bio-Pharma Inc., a Canadian pharmaceutical firm that specializes in cannabinoid-derived drug therapy, has recently initiated a clinical study of synthetic cannabinoid therapy (PPP003v) for ophthalmic eye pain in ...

Satipharm begins clinical trial of CBD capsules for treating menopause
Satipharm begins clinical trial of CBD capsules for treating menopause
By Saipriya Iyer

Cannabis was prior considered to possess various medicinal benefits for treating diseases. However, after years of restriction, the scientific community is finally exploring the medical avenues of CBD by conducting adv...